4.3 Review

Identification of people with heterozygous familial hypercholesterolemia

期刊

CURRENT OPINION IN LIPIDOLOGY
卷 23, 期 4, 页码 282-289

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOL.0b013e3283556c33

关键词

cascade screening; familial hypercholesterolemia; genetic testing; universal screening

资金

  1. National Institutes of Health [NIH T32 DK 007120]
  2. Amarin
  3. Abbott
  4. ISIS/Genzyme
  5. Regeneron/Sanofi-Aventis
  6. Merck
  7. GlaxoSmith-Kline
  8. Genentech

向作者/读者索取更多资源

Purpose of review Familial hypercholesterolemia is an underdiagnosed autosomal codominant genetic condition associated with significantly increased risk of early cardiovascular disease when untreated. Early diagnosis and treatment decrease the excess risk, and strategies for identification of affected individuals are being developed worldwide. This review will discuss, from a clinician's perspective, some of the issues involved in identifying people with familial hypercholesterolemia. Recent findings Several sets of recommendations have been published outlining the strategies for identification of people with familial hypercholesterolemia in various countries and regions. These include Australasia, Europe, and the USA. Summary Continuing efforts to find the best methods for identification of people with familial hypercholesterolemia are needed to ensure that this very treatable inherited condition is diagnosed early enough to prevent the development of atherosclerotic vascular disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据